To improve the success of new products, Johnson & Johnson has made several organizational changes to its new product development process. It creates internal startups to replicate venture capital firms and promotes greater input from doctors and insurers. It also appointed a Chief Science & Technology Officer to oversee R&D. One notable success from these changes was the $2.6 billion CYPHER drug-coated cardiac stent. Stage-gate systems and cross-functional teams are two common approaches used by companies to organize their new product development. These systems divide the process into stages with checkpoints to review projects, helping companies focus resources on the most promising ideas.